Across 313 European CTIS cardiology Phase II and Phase III trial records, the most frequent measured endpoint domains were safety/adverse events in 171 records (54.6%), composite clinical outcomes in 165 (52.7%), and mortality/survival in 156 (49.8%). Phase III trials were more outcome-driven, while Phase II trials emphasized safety, biomarkers, diagnostic/imaging, and hemodynamic endpoints.
Safety/adverse events appeared in 171 of 313 records (54.6%), composite clinical outcomes in 165 (52.7%), mortality/survival in 156 (49.8%), and biomarkers in 137 (43.8%). This shows that cardiology trial endpoint design is heavily anchored in hard clinical outcomes, even outside Phase III.
European cardiology trials are not endpoint-light: they combine safety, survival, hospitalization, biomarkers, imaging, and patient-reported measures. The leading pattern is a layered endpoint strategy rather than reliance on a single cardiovascular outcome.
The dataset contained 448 primary endpoint instances, 1,682 secondary endpoint instances, and 24 exploratory/other endpoint instances. Composite clinical outcomes were the most common primary domain, appearing as a primary endpoint in 107 of 313 records (34.2%), followed by mortality/survival in 89 (28.4%).
| Domain | Primary | Secondary | Exploratory / other |
|---|---|---|---|
| Composite clinical outcomes | 107 / 313 | 141 / 313 | 2 / 313 |
| Mortality / survival | 89 / 313 | 135 / 313 | 0 / 313 |
| Safety / adverse events | 62 / 313 | 127 / 313 | 0 / 313 |
| Biomarkers | 50 / 313 | 122 / 313 | 0 / 313 |
| Diagnostic / imaging performance | 49 / 313 | 79 / 313 | 5 / 313 |
| Hospitalization / urgent care | 44 / 313 | 92 / 313 | 1 / 313 |
Primary endpoints concentrate on registrationally meaningful clinical outcomes, while secondary endpoints carry most of the mechanistic, imaging, biomarker, quality-of-life, and utilization burden.
Among 106 Phase II records, safety/adverse events appeared in 69 (65.1%) and biomarkers in 53 (50.0%). Among 207 Phase III records, mortality/survival appeared in 121 (58.5%) and composite clinical outcomes in 118 (57.0%).
The phase split is clear: Phase II cardiology trials are signal-finding and safety-heavy, while Phase III trials are built around clinical events, mortality, and hospitalization outcomes that support EU regulatory and reimbursement interpretation.
Heart failure/cardiomyopathy was the largest disease cluster with 92 of 313 records (29.4%). It was followed by lipid/ASCVD prevention with 41 records (13.1%), vascular/valve disease with 33 (10.5%), pulmonary hypertension with 20 (6.4%), hypertension/aldosteronism with 19 (6.1%), and arrhythmia with 17 (5.4%).
The disease signal is clinically coherent: pulmonary hypertension relies on functional/hemodynamic endpoints, lipid/ASCVD studies rely on lipid and imaging markers, arrhythmia trials rely on rhythm endpoints, and heart failure/cardiomyopathy trials combine composite events, mortality, biomarkers, and patient-reported outcomes.
Small molecules dominated the dataset with 212 records, but biologics, oligonucleotide/RNA/gene approaches, and radiopharmaceutical/diagnostic agents showed distinct endpoint signatures. Radiopharmaceutical/diagnostic records were the most imaging-heavy, with diagnostic/imaging performance in 12 of 14 records (85.7%).
| Modality group | Records | Most frequent endpoint domains |
|---|---|---|
| Small molecule | 212 | Composite 116 (54.7%), mortality 113 (53.3%), safety 112 (52.8%) |
| Protein / antibody biologic | 65 | Safety 44 (67.7%), biomarkers 38 (58.5%), mortality 37 (56.9%) |
| Oligonucleotide / RNA / gene | 27 | Composite 20 (74.1%), safety 17 (63.0%), mortality 15 (55.6%) |
| Radiopharmaceutical / diagnostic | 14 | Diagnostic/imaging 12 (85.7%), safety 8 (57.1%), biomarkers 6 (42.9%) |
Endpoint planning should not be separated from modality. Imaging and diagnostic agents require diagnostic-performance endpoints, biologics add biomarker and safety intensity, and advanced genetic/RNA approaches still need clinical outcome anchoring in cardiology.
Across all 313 CTIS records, the median initial CTIS submission-to-first authorization interval was 98 days. Phase III records had a median of 100 days compared with 91 days for Phase II. Among primary endpoint categories with at least 20 records, lipid/metabolic primary endpoints had the longest median interval at 115 days, followed by diagnostic/imaging primary endpoints at 110 days.
For EU submissions, endpoint strategy is also an operational planning variable. CTIS timelines were not only phase-dependent; they also varied by the type of primary endpoint, with lipid/metabolic and diagnostic/imaging primary endpoints showing longer median authorization intervals than cardiac-function primary endpoints.
The same endpoint data also answers which disease areas require the most complex measurement packages, which trial phases are most outcomes-driven, and where CTIS timing should be watched during EU planning.
Composite clinical outcomes include MACE-like cardiovascular composites, win-ratio or hierarchical composites, and multi-component endpoints involving death, hospitalization, cardiovascular events, renal events, transplant, ventricular assist device, or similar clinical events. Biomarkers include NT-proBNP, BNP, troponin, renal biomarkers, inflammatory markers, lipid biomarkers when not analyzed as the main lipid/metabolic domain, and laboratory-based mechanistic measures. CTIS means Clinical Trials Information System.